In a randomized clinical trial34 of 295 patients with moderate-to-severe AD who were receiving a stable cholinesterase inhibitor therapy, discontinuation of donepezil was not associated with a difference in long-term care institutionalization at 3 years. This evidence concerns the gene BCHE and Alzheimer disease.